- $237.48bn
- $280.79bn
- $36.75bn
Medical journal retracts paper on Amgen’s Tavneos drug trial after FDA findings
Viridian jumps after US FDA approves thyroid eye disease drug
US FDA greenlights Viridian's thyroid eye disease drug (updated)
US FDA greenlights Viridian's eye disease drug
U.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
U.S. STOCKS ON THE MOVE-Fortrea, Nuvation Bio, Acadia Pharmaceuticals
U.S. STOCKS ON THE MOVE-Crocs, Amgen, Synaptics
Amgen up after EMA recommends revoking marketing authorization for rare-disease drug
EU regulator backs revoking Amgen's right to sell rare-disease drug (updated)
EMA recommends revoking marketing authorisation for Amgen's rare disease drug
Brief: EMA Recommends Revoking Marketing Authorisation For Tavneos In EU
Factbox: Global drugmakers invest billions to boost US presence
China's Harbour BioMed to focus on another patent case after $20 million damages award
Amgen owes $20.2 million in antibody patent lawsuit, US jury says (updated)
Amgen owes $20.2 mln in antibody patent lawsuit, US jury says
Amgen taps research firm to reassess Tavneos data (updated)
Brief: EMA's PRAC Agrees On DHPC For Tavneos On Reinforced Liver Monitoring Requirements
Amgen taps research firm to reassess Tavneos data